Jefferies slashes price target on Arbutus Biopharma Corporation [ABUS] – find out why.

Related

Arbutus Biopharma Corporation [NASDAQ: ABUS] loss -3.71% on the last trading session, reaching $4.15 price per share at the time. The company report on December 1, 2021 that Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus (cHBV) infection and to treat coronaviruses (including COVID-19), announced preliminary data from its on-going Phase 1a/1b clinical trial demonstrating that its next generation capsid inhibitor, AB-836, is generally safe and well-tolerated in both healthy subjects and patients with cHBV and provides robust antiviral activity.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Gaston Picchio, Ph.D., Chief Development Officer at Arbutus, commented, “These preliminary results demonstrate that AB-836 is generally safe and well-tolerated in both single- and multiple-doses in healthy subjects and at doses up to 100mg administered once daily for 28 days in cHBV patients. In addition, the mean Day 28 drop in HBV DNA observed to date with a relatively low dose suggests that AB-836 is a very potent inhibitor of HBV replication making it an ideal candidate to potentially completely suppress viral replication. We look forward to continuing to evaluate the safety and efficacy of AB-836 in Part 3 of this trial.”.

Arbutus Biopharma Corporation represents 101.29 million in outstanding shares, while the company has a total market value of $561.37 million with the latest information. ABUS stock price has been found in the range of $3.92 to $4.45.

If compared to the average trading volume of 8.71M shares, ABUS reached a trading volume of 18042543 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Arbutus Biopharma Corporation [ABUS]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABUS shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABUS stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Arbutus Biopharma Corporation shares, keeping their opinion on the stock as Hold, with their previous recommendation back on February 25, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 17, 2020, representing the official price target for Arbutus Biopharma Corporation stock. Previously, the target price had yet another drop from $10 to $8, while JMP Securities kept a Mkt Outperform rating on ABUS stock.

The Average True Range (ATR) for Arbutus Biopharma Corporation is set at 0.45, with the Price to Sales ratio for ABUS stock in the period of the last 12 months amounting to 55.04.

Trading performance analysis for ABUS stock

Arbutus Biopharma Corporation [ABUS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.59. With this latest performance, ABUS shares gained by 7.79% in over the last four-week period, additionally plugging by 26.91% over the last 6 months – not to mention a rise of 5.33% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABUS stock in for the last two-week period is set at 61.30, with the RSI for the last a single of trading hit 64.92, and the three-weeks RSI is set at 58.51 for Arbutus Biopharma Corporation [ABUS]. The present Moving Average for the last 50 days of trading for this stock 3.87, while it was recorded at 3.88 for the last single week of trading, and 3.41 for the last 200 days.

Arbutus Biopharma Corporation [ABUS]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Arbutus Biopharma Corporation [ABUS] shares currently have an operating margin of -828.30. Arbutus Biopharma Corporation’s Net Margin is presently recorded at -921.97.

Return on Total Capital for ABUS is now -52.16, given the latest momentum, and Return on Invested Capital for the company is -58.25. Return on Equity for this stock declined to -72.97, with Return on Assets sitting at -52.55. When it comes to the capital structure of this company, Arbutus Biopharma Corporation [ABUS] has a Total Debt to Total Equity ratio set at 22.10. Additionally, ABUS Total Debt to Total Capital is recorded at 18.10, with Total Debt to Total Assets ending up at 16.44.

Reflecting on the efficiency of the workforce at the company, Arbutus Biopharma Corporation [ABUS] managed to generate an average of -$817,244 per employee. Receivables Turnover for the company is 5.50 with a Total Asset Turnover recorded at a value of 0.06.Arbutus Biopharma Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.50 and a Current Ratio set at 12.50.

Arbutus Biopharma Corporation [ABUS]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Arbutus Biopharma Corporation posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -22.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABUS.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at Arbutus Biopharma Corporation [ABUS]

There are presently around $145 million, or 26.30% of ABUS stock, in the hands of institutional investors. The top three institutional holders of ABUS stocks are: BLACKROCK INC. with ownership of 5,935,203, which is approximately 1.707% of the company’s market cap and around 28.70% of the total institutional ownership; RTW INVESTMENTS, LP, holding 4,733,323 shares of the stock with an approximate value of $19.64 million in ABUS stocks shares; and VANGUARD GROUP INC, currently with $15.63 million in ABUS stock with ownership of nearly 0.796% of the company’s market capitalization.

Positions in Arbutus Biopharma Corporation stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 56 institutional holders increased their position in Arbutus Biopharma Corporation [NASDAQ:ABUS] by around 8,851,143 shares. Additionally, 37 investors decreased positions by around 3,035,192 shares, while 22 investors held positions by with 23,031,896 shares. The mentioned changes placed institutional holdings at 34,918,231 shares, according to the latest SEC report filing. ABUS stock had 25 new institutional investments in for a total of 3,824,239 shares, while 15 institutional investors sold positions of 675,589 shares during the same period.